An open, non-randomized, parallel-group pharmokinetic and -dynamic, investigator-initiated study on effects of obeticholic acid (OCA) in bile of patients with primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) in comparison to healthy controls

Trial Profile

An open, non-randomized, parallel-group pharmokinetic and -dynamic, investigator-initiated study on effects of obeticholic acid (OCA) in bile of patients with primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) in comparison to healthy controls

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Obeticholic acid (Primary)
  • Indications Alcoholic hepatitis; Biliary atresia; Cholelithiasis; Non-alcoholic steatohepatitis; Obesity; Primary biliary cirrhosis; Primary sclerosing cholangitis
  • Focus Pharmacokinetics
  • Acronyms OCABILE
  • Most Recent Events

    • 11 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top